Outcome of myeloablative allogeneic stem cell transplantation in multiple myeloma with a 153Sm-EDTMP-based preparative regimen.
Kennedy
G A
GA
Durrant
S
S
Butler
J
J
Morton
J
J
Western
R
R
Bartlett
M L
ML
Allison
R
R
MacFarlane
D J
DJ
D000328:Adult; D018572:Disease-Free Survival; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000532:radiotherapy*; D009942:Organometallic Compounds / Q000627:therapeutic use*; D009943:Organophosphorus Compounds / Q000627:therapeutic use*; D011868:Radioisotopes / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D015203:Reproducibility of Results; D012493:Samarium / Q000627:therapeutic use*; D013997:Time Factors; D019172:Transplantation Conditioning / Q000379:methods; D014184:Transplantation, Homologous; D016896:Treatment Outcome
D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D011868:Radioisotopes; D012493:Samarium; C061972:samarium Sm-153 lexidronam